Eli Lilly Stock Keeps Climbing After Drugmaker's Strong Earnings Report

Key TakeawaysIt was a second straight day of gains for Eli Lilly shares following the drugmaker's blowout second-quarter earnings report.Lilly exceeded earnings and revenue forecasts and boosted its guidance as it posted a big jump in sales of its weight-loss drugs Mounjaro and Zepbound.Mounjaro and Zepbound sales made up nearly 40% of Lilly's quarterly revenue. Investors of Eli Lilly (LLY) continued to ride the wave created by the pharmaceutical firm’s powerhouse second-quarter earnings report.  Shares soa ...